HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Capsaicin (Zostrix)

An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.

Also Known As:

Zostrix; 8-Methyl-N-Vanillyl-6-Nonenamide; Alacan Brand of Capsaicin; Antiphlogistine Rub A-535 Capsaicin; Axsain; Capsaicine; Capsicum Farmaya; Capsidol; Capsin; Capzasin; Carter Horner Brand of Capsaicin; Centrum Brand of Capsaicin; Elan Brand of Capsaicin; Flemming Brand of Capsaicin; Gelcen; Katrum; Link Brand of Capsaicin; Medicis Brand of Capsaicin; NGX-4010; Smaller Brand of Capsaicin; Thompson Brand of Capsaicin; Vinas Brand of Capsaicin; Zacin; 8 Methyl N Vanillyl 6 Nonenamide; NGX 4010; NGX4010; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-

Networked: 3748 relevant articles (275 outcomes, 675 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Arendt-Nielsen, Lars: 42 articles (05/2015 - 01/2002)
2.	Fujimura, Masaki: 25 articles (06/2015 - 04/2002)
3.	Millqvist, Eva: 23 articles (01/2015 - 06/2002)
4.	Arendt-Nielsen, L: 23 articles (10/2011 - 01/2000)
5.	Szolcsányi, János: 21 articles (05/2015 - 05/2004)
6.	Svensson, Peter: 18 articles (06/2015 - 07/2002)
7.	Dicpinigaitis, Peter V: 18 articles (06/2015 - 06/2002)
8.	Tatar, M: 18 articles (01/2013 - 01/2003)
9.	Helyes, Zsuzsanna: 17 articles (09/2015 - 05/2004)
10.	Ternesten-Hasséus, Ewa: 16 articles (01/2015 - 10/2002)

Related Diseases

1.	Pain (Aches) 03/01/2004 - "Capsaicin specifically activates or destroys small diameter nociceptive sensory neurons that contain the capsaicin receptor, also called vanilloid receptor 1. Neurons sensitive to capsaicin mediate inflammatory pain and are important targets for management of chronic pain. " 01/01/2014 - "The study did not demonstrate significant differences in pain relief between capsaicin and placebo treatment, although a trend toward pain improvement in capsaicin treated patients was observed 1 month after patch application. " 01/01/2012 - " a mixed population trial, qualitative analysis of patients with RA showed a significantly greater reduction in pain favouring topical capsaicin over placebo at one and two weeks (MD -23.80, 95% CI -44.81 to -2.79; NNT 3, 95% CI 2 to 47; MD -34.40, 95% CI -54.66 to -14.14; NNT 2, 95% CI 1.4 to 6 respectively). " 10/01/2010 - "In pivotal, randomized, double-blind, multicentre trials in adults with PHN, a single 60-minute application of capsaicin dermal patch reduced the mean Numeric Pain Rating Scale (NPRS) scores from baseline to a significantly greater extent than a low-concentration (0.04% w/w capsaicin) control patch during weeks 2-8. In randomized, double-blind, multicentre trials in patients with HIV-associated neuropathy, capsaicin dermal patch reduced the mean NPRS scores from baseline significantly more than control in one study for the 30- and 90-minute, but not the 60-minute, application during weeks 2-12. " 08/01/2013 - "This analysis demonstrates that in clinical practice, the capsaicin 8% patch provides rapid and sustained pain reductions in patients with a variety of PNP conditions and a significant reduction in prescribed concomitant NP medications. "
2.	Neuralgia (Stump Neuralgia) 01/01/2016 - "Topical high-dose capsaicin acting on TRPV1 receptors and inducing an intraepidermal decrease in the small nerve fibre count is effective in treating neuropathic pain (NP). " 04/01/1990 - "Clinical trials of topical capsaicin treatment for post-herpetic neuralgia have yielded promising results. " 06/01/2013 - "Analgesic treatment of peripheral neuropathic pain with the capsaicin 8% cutaneous patch is safe and effective. " 05/01/2013 - "The capsaicin 8% cutaneous patch is an emergent new treatment option for patients with peripheral neuropathic pain. " 01/01/2013 - "The capsaicin 8% patch is a novel treatment option that directly targets the source of peripheral neuropathic pain. "
3.	Hyperalgesia 02/01/2001 - "Selective blockade of peripheral NK1 receptors in WT mice resulted in a complete inhibition of capsaicin-evoked plasma extravasation, but the mechanical hyperalgesia induced by 30 microg capsaicin intraplantar was still significantly greater than that seen in KO mice. " 01/01/2014 - "Our data suggest that intrathecal capsaicin could significantly attenuate thermal hyperalgesia, depending on the time when the drug is given after nerve injury, and that the antinociceptive efficacy of intrathecal capsaicin positively correlates with the previously reported dynamic profile of spinal transient receptor potential vanilloid 1 activity after nerve injury." 01/01/2011 - "To develop improved methods to assess single-sweeps, we applied a new approach in one healthy volunteer participating in a placebo controlled study of widespread hyperalgesia induced by perfusion of acid and capsaicin in the esophagus. " 07/01/1998 - "Intradermal and topical application of capsaicin have been used to study mechanisms of mechanical allodynia (MA) and pinprick hyperalgesia (PPH) and the efficacy of drugs in relieving these symptoms. " 11/01/2015 - "The aim of the present study was to characterize, using EEG, the effects of pinprick stimulation intensity on the magnitude of pinprick-elicited brain potentials [event-related potentials (ERPs)] before and after secondary hyperalgesia induced by intradermal capsaicin in humans. "
4.	Cough 01/01/2007 - "A novel pyridazinylpiperazine analog TPRV-1 inhibitor can inhibit the cough reflex, induced by both low pH and capsaicin, suggesting that it could be clinically beneficial in treatment of cough." 01/01/2007 - "The capsaicin concentration threshold for eliciting a cough was significantly greater, 39.3 microM (+/-5.6 SEM). " 01/01/2006 - "Compared with tidal breathing, inhalation of capsaicin with the dosimeter method caused a significantly greater number of coughs and respiratory symptoms in both patients and controls. " 10/19/2005 - "There was a significant improvement in the Leicester Cough Questionnaire symptom scores from 80.8 points (SD 13.2) to 95.1 (SD 17) (p = 0.02) and in a 6-point scale of cough scores, but there was no change in capsaicin cough response. " 06/01/2002 - "Suplatast improved the cough scores and the cough threshold for capsaicin in patients with CVA without significant side effects, suggesting the effectiveness of suplatast in the treatment of CVA. "
5.	Pruritus (Itching) 01/01/1992 - "Eight of nine evaluable patients in the open-label trial reported marked relief or complete resolution of itching during the study period, and two of five evaluable patients in the double-blind trial reported complete resolution of itching in the capsaicin-treated arm with no or minimal improvement in the vehicle-treated arm. " 08/01/2010 - "The final study on brachioradial pruritus used an inappropriate design and reported no significant reduction in itch between capsaicin and placebo. " 03/01/1994 - "Ten of thirteen patients completing the capsaicin-cream study found significant relief (itching much improved or gone) after 3 weeks compared with the untreated control arm. " 01/01/2008 - "Both groups showed a significant decrease in pruritus, scaling, and skin dryness (p<0.05), but burning sensation was not improved significantly in the capsaicin group. " 04/01/1997 - "Capsaicin was significantly more effective in alleviating uremic pruritus than the placebo, and no serious side effects were noted. "

Related Drugs and Biologics

1.	Capsaicin (Zostrix)
2.	Lidocaine (Xylocaine)
3.	Substance P
4.	Opioid Analgesics (Opioids)
5.	resiniferatoxin
6.	Anticonvulsants (Antiepileptic Drugs)
7.	Antidepressive Agents (Antidepressants)
8.	gabapentin (Neurontin)
9.	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)
10.	pregabalin (Lyrica)

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Renal Dialysis (Hemodialysis)
3.	Analgesia
4.	Aftercare (After-Treatment)
5.	Intradermal Injections